Literature index · Română
Research references
Research use only. Papers below are public literature. They do not describe SiAna vials and are not protocols or medical advice.
BPC-157
Sikiric et al., 1996 · PMID 8769287
- Pentadecapeptide reduced gastric lesions from ethanol, restraint stress and indomethacin in rats.
- Capsaicin damage to sensory neurons weakened that protection.
- Authors linked the effect to intact capsaicin-sensitive afferents.
Xue et al., 2004 · PMID 15052688
- IM and IG BPC-157 reduced ulcer area in acute and chronic rat models.
- Intramuscular dosing outperformed the gastric route at lower dose.
- Healing was faster than untreated controls after acetate challenge.
Sikiric et al., 2020 · PMID 31158953
- Review frames BPC-157 as a candidate mediator of Robert-type cytoprotection.
- Summarises multi-organ lesion models beyond the stomach.
- Notes stability in gastric juice and a wide published preclinical range.
TB-500 / thymosin β4
Goldstein et al., 2012 · PMID 22074294
- Tβ4 binds G-actin and is released after injury from platelets and macrophages.
- Review lists migration, angiogenesis and lower myofibroblast/scar signalling.
- Discusses dermal, corneal, cardiac and CNS repair programmes.
Esposito et al., 2012 · PMID 22962027
- Commercial TB-500 contained Ac-LKKTETQ (Tβ4 fragment 17–23).
- Fragment confirmed by HRMS and by independent peptide synthesis.
- Proposed plasma/urine LC-MS detection for anti-doping work.
Ruff et al., 2010 · Ann N Y Acad Sci
- IV full-length Tβ4 studied in healthy volunteers, placebo-controlled.
- Single- and multi-dose arms; half-life rose with dose.
- Safety lab set for the intact 43-aa protein, not the 7-aa fragment.
Retatrutide
Jastreboff et al., 2023 · PMID 37366315
- Phase 2, 338 adults; agonist at GIP, GLP-1 and glucagon receptors.
- At 48 weeks, mean weight change reached −24.2% on 12 mg vs −2.1% placebo.
- Higher doses had more GI events typical of incretin agonists.
Coskun et al., 2022 · Cell Metab
- LY3437943 characterised as a balanced triple agonist in vitro and in vivo.
- Rodent and primate data showed energy-expenditure plus incretin effects.
- Supported later human dose selection.
Tirzepatide
Jastreboff et al., 2022 · SURMOUNT-1 · DOI 10.1056/NEJMoa2206038
- Phase 3, 2,539 adults with obesity, no diabetes, 72 weeks.
- Mean weight change −15.0% / −19.5% / −20.9% at 5 / 10 / 15 mg vs −3.1% placebo.
- Most of the loss on DXA substudies was fat mass.
Frias et al., 2021 · PMID 34170647
- SURPASS-2: once-weekly tirzepatide vs semaglutide 1 mg in T2D.
- Greater HbA1c and weight reduction on tirzepatide arms.
- GI adverse events were the main tolerability limit on both drugs.
Tesamorelin
Falutz et al., 2007 · NEJM 357:2359
- GHRH analogue in adults with HIV-associated abdominal fat accumulation.
- CT-measured visceral adipose tissue fell vs placebo over 26 weeks.
- IGF-1 rose as expected for a GHRH secretagogue.
Stanley et al., 2014 · JAMA 312:380
- Randomised trial: tesamorelin reduced VAT and liver fat on imaging.
- Subcutaneous fat was largely spared.
- VAT and liver fat rose again after treatment stopped.
Semax
Ashmarin / Myasoedov series (1990s–2000s)
- ACTH(4–10) analogue designed for CNS work without steroidogenic ACTH activity.
- Russian experimental papers report nootropic and neuroprotective readouts.
- Human literature is mostly the same research groups; limited Western RCTs.
Medvedeva et al., 2014 · PMID 25471289
- Transcriptome study after Semax in a rat model.
- Changed genes clustered in immune and vascular pathways.
- Supports a gene-expression, not only neurotransmitter, research angle.
PT-141
Molinoff et al., 2003 · PMID 12658171
- Bremelanotide is a melanocortin receptor agonist (MC3R/MC4R family).
- Early work positioned it for sexual-function pharmacology, not PDE5.
- Central melanocortin signalling was the proposed mechanism.
Kingsberg et al., 2019 · PMID 31599840
- RECONNECT: two Phase 3 trials in premenopausal HSDD.
- On-demand subcutaneous bremelanotide beat placebo on desire scores.
- Nausea and flushing were the common adverse events.
Epitalon
Khavinson et al., 2003 · PMID 12937682
- Ala-Glu-Asp-Gly reported to induce telomerase activity in human somatic cells in vitro.
- Authors also reported telomere lengthening in that system.
- Independent replication outside the St Petersburg group is sparse.
Khavinson & Anisimov reviews
- Peptide bioregulators framed as gerontology tools in Russian literature.
- Human data are largely open-label or observational from one institute.
- Western reviewers treat the evidence as low-certainty.
GHK-Cu
Pickart & Margolina, 2018 · PMID 29986520
- Review of GHK-Cu gene-expression datasets (skin, antioxidant, repair genes).
- Copper-binding tripeptide discussed as a matrix-remodelling signal.
- Most cited work is in vitro / dermal, not large RCTs.
Pickart, 2008 · PMID 18644225
- Classic review of GHK in tissue remodelling and wound models.
- Describes collagen, glycosaminoglycan and anti-inflammatory readouts.
- Sets the biochemical story later gene papers expanded.
MOTS-c
Lee et al., 2015 · PMID 25738455
- mtDNA-encoded 16-aa peptide improved metabolic homeostasis in mice.
- Prevented diet-induced obesity and insulin resistance in that model.
- AMPK / folate-methionine pathway implicated.
Kim et al., 2018 · PMID 29983246
- MOTS-c can move to the nucleus under metabolic stress.
- There it alters nuclear gene expression.
- Links a mitochondrial ORF to nuclear transcriptional control.
5-Amino-1MQ
Neelakantan et al. · PMID 29702097
- Membrane-permeable small-molecule NNMT inhibitors described.
- 5-amino-1-methylquinolinium analogues used as tool compounds.
- Aim was NAD+ / methylation research in cells, not a registered drug trial.
Kraus et al., 2014 · PMID 24717514
- NNMT knockdown in mice protected against diet-induced obesity.
- Raised SAM and NAD+ related metabolites in adipose tissue.
- Gave the enzyme-target rationale later 1MQ analogues used.
WhatsApp +40 729 659 080 for questions about an order.
